Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Intellegens and Optibrium celebrate success in global challenge to find novel antimalarial compounds

publication date: Dec 16, 2019
 | 
author/source: Optibrium

intellegens-and-optibrium-celebrate-success-global


Team deploy Alchemite™ deep learning platform to predict active compounds for malarial drug discovery

Intellegens, an artificial intelligence (AI) start-up, and, Optibrium™, leading providers of software and services for drug discovery, have announced joint success in the Open Source Malaria (OSM) global initiative aimed at identifying the best predictive models for antimalarial compounds. Together, the companies developed one of the top models, deploying a cutting-edge deep neural network algorithm [1], Alchemite™, to accurately predict active compounds with novel mechanisms of actions that could be critical to future malaria control and elimination. As one of four prizewinning models selected, the project will now progress through the next phase of the initiative that includes the proposal of new compounds that are predicted to be active, for synthesis and testing against the malaria parasite.

Founded in 2012 by Professor Matthew Todd, Chair of Drug Discovery at University College London, the OSM consortium aims to find a new medicine for the treatment of malaria, which is formally recognised as a neglected tropical disease by the World Health Organisation. Over the past six years, OSM has brought together an international team of researchers who design, synthesise and test new antimalarial candidates that they hope will demonstrate potent activity against Plasmodium falciparum, the deadliest species of the malaria-causing parasite, in vitro and in vivo.

In the latest phase of the initiative, Intellegens’ predictive modelling platform Alchemite, applied by Optibrium, has been commended for its ability to predict active compounds with a novel mechanism of action. Alchemite has shown to significantly improve the accuracy of the predictions and outperform conventional quantitative structure-activity relationship (QSAR) models and other well-known approaches, thereby reducing research and development costs associated with the unneeded synthesis of inactive compounds.

Dr Tom Whitehead, Machine Learning Scientist at Intellegens, commented: “Alchemite demonstrates real-world applicability and has the potential to provide accurate predictions for problems in drug discovery, such as finding active compounds that can counteract tropical diseases like Malaria.”

Dr Benedict Irwin, Senior Scientist at Optibrium, said: “In order to combat the increasing incidences of resistance to antimalarial medication, it is essential to discover new compounds with novel mechanisms of action. We have previously seen that the Alchemite method can add significant predictive value across a range of projects and data sets both large and small. The Open Source Malaria data set was a new challenge and we are thrilled that our partnership with Intellegens has been recognised by the consortium and we look forward to progressing to the next phase of the initiative.”

Professor Matthew Todd, Founder of the OSM consortium, added: “It's frequently the case in infectious disease drug discovery that we're working without knowledge of the mechanism of action. This so-called phenotypic drug discovery can make it a challenge to see the patterns in the data in order to predict what to make next. I hope that new developments in AI and machine learning (ML) can help us to make our research more predictive and hence more efficient. The recent competition in Open Source Malaria, where teams openly contributed models to improve a promising series of antimalarials, suggests that new AI/ML technologies have enormous promise. Congratulations to the Optibrium/Intellegens team for contributing one of the best models, using Alchemite. We're excited by the new molecules that were suggested because they are not ones that we would necessarily have thought of ourselves. We're now making them in the lab.”

[1] Whitehead et al. J. Chem. Inf. Comput. Model. (2019) 59(3) pp. 1197-1204

 

more about optibrium

more about intellegens


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events